---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-26-000003"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:51:11.422752+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akebia expects Q4 2025 Vafseo net revenue $5-6M; dosed first patient in praliciguat Phase 2

## Summary
- Vafseo Q4 net product revenue expected $5-6M (vs. underlying dosing demand $10.5-11.5M) due to $4.5-5M inventory adjustment at USRC.
- Total Q4 prescribers ~785 (+8% QoQ); at least 25% of new patients from non-USRC centers (up from <10% Q3).
- First patient dosed in praliciguat Phase 2 trial for FSGS; AKB-097 basket study starts H2 2026.
- VOICE Phase IV fully enrolled (2,100+ patients); topline early 2027; VOCAL trial data expected Q4 2026.
- Revenue growth expected to resume Q1 2026; broad prescribing access to ~275,000 dialysis patients.

## SEC filing metadata
- accession: 0001517022-26-000003
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000003/0001517022-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000003/akba-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-26-000003
- JSON: https://secwatch.observer/filing/0001517022-26-000003.json
- Plain text: https://secwatch.observer/filing/0001517022-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.